Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 1—January 2011

Letter

Carbapenemases in Enterobacteria, Hong Kong, China, 2009

Yiu-Wai ChuComments to Author , Viola W.N. Tung, Terence K.M. Cheung, Man-Yu Chu, Naomi Cheng, Christopher Lai, Dominic N.C. Tsang, and Janice Y.C. Lo
Author affiliations: Author affiliations: Centre for Health Protection, Hong Kong Special Administrative Region, People’s Republic of China (Y.-W. Chu, V.W.N. Tung, T.K.M. Cheung, M.-Y. Chu, J.Y.C. Lo); Queen Elizabeth Hospital, Hong Kong (N. Cheng, C. Lai, D.N.C. Tsang)

Main Article

Table

Antimicrobial susceptibility results and ESBL detected for 4 carbapenemase-harboring enterobacteria isolates, Hong Kong, 2009*

Organism Patient age, y/ sex Patient location Specimen MIC, μg/mL (CLSI breakpoint for resistance)†
ESBL/
carbapenemase detected
IMP
(>4) MEM (>4) ERT
(>1) NA
(>32) CIP
(>4) NIT (>128) AK
(>64) GN
(>16) SXT (>80)
Citrobacter freundii 69/M Hospital Sputum 8 >16 >8 >32 >4 128 <2 8 >320 IMP-4, CTX-M-9
Klebsiella pneumoniae 60/M Hospital Bedsore >16 >16 >8 >32 >4 >512 16 <1 >320 IMP-4
Enterobacter cloacae 68/F Hospital Urine >16 >16 >8 4 <0.25 64 <2 <1 <20 IMI-3
Escherichia coli 64/M Outpatient clinic Urine 4 2 4 <2 <0.25 <16 >256 >16 <20 NDM-1

*ESBL, extended-spectrum β-lactamase; IMP, imipenem; MEM, meropenem; ERT, ertapenem; NA, nalidixic acid; CIP, ciprofloxacin; NIT, nitrofurantoin; AK, amikacin; GN, gentamicin; SXT, co-trimoxazole; NDM-1, New Delhi metallo-β-lactamase.
†CLSI, Clinical and Laboratory Standards Institute, updated June 2010.

Main Article

TOP